Prothena Corporation plc is a late-stage clinical
         biotechnology company focused on the discovery,
      development and commercialization of novel
   protein immunotherapies for the potential
  treatment of diseases that involve
amyloid or cell adhesion.

LATEST NEWS

SPOTLIGHT

Our Phase 2b PRONTO and Phase 3 VITAL Studies are online »

PRONTO Study

Potential Mechanism of Action (MOA) Videos:

vid_neod001for AL Amyloidosis

vid_prx002for Parkinson’s Disease and
Other Related Synucleinopathies
vid_prx003for Psoriasis and Other
Inflammatory Diseases